An Act protecting patient safety regarding non-FDA approved drugs
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Overview
This bill aims to enhance patient safety in Massachusetts by addressing the use of non-FDA approved drugs. It seeks to establish procedures and safeguards related to the distribution and use of these medications, recognizing potential risks to public health. The bill updates existing regulations to better protect patients from harm associated with unregulated drug products. It is a response to concerns about the increasing availability and use of such drugs.
Key provisions
- Requires reporting of sales and distribution of non-FDA approved drugs.
- Establishes guidelines for healthcare providers regarding the prescription and dispensing of these drugs.
- Mandates labeling requirements for non-FDA approved drugs to clearly identify potential risks.
- Creates a process for reviewing and assessing the safety of non-FDA approved drugs.
- Focuses on preventing the importation of non-FDA approved drugs.
- Addresses the use of these drugs in compounding pharmacies.
- Requires healthcare facilities to have policies in place regarding the use of non-FDA approved drugs.
Who is affected
- Patients in Massachusetts
- Healthcare providers (doctors, pharmacists, etc.)
- Pharmaceutical companies
- Compounding pharmacies
- The Massachusetts Department of Public Health
Notable changes
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
1 on record
Primary sponsor
Joint Committee on Health Care Financing
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours